Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...
Earnings Report 5.284 USD Q4 2024 Earnings Release 02/06/2025 Earnings Report 4.894 USD Q1 2025 Earnings Release 05/01/2025 Earnings Report 5.682 USD Q2 2025 Earnings Release 08/07/2025 Earnings ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
Citi lowered the firm’s price target on AbbVie (ABBV) to $205 from $215 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the ...
Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...
Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...
Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers.